Zhi Yu1, Tao Huang2,3, Yan Zheng4, Tiange Wang5, Yoriko Heianza5, Dianjianyi Sun5, Hannia Campos4, Lu Qi6,5. 1. Division of Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Boston, MA. 2. Epidemiology Domain, Saw Swee Hock School of Public Health, and. 3. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 4. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA; and. 5. Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA. 6. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA; and lqi1@tulane.edu.
Abstract
Background: Previous studies have indicated that the cardioprotective effects of long-chain (LC) n-3 (ω-3) polyunsaturated fatty acids (PUFAs) may vary across various ethnic populations. Emerging evidence has suggested that the gene-environment interaction may partly explain such variations. Proprotein convertase subtilisin/kexin type 9 (PCSK9) was shown to have a mutually regulating relation with LC n-3 PUFAs and also to reduce the risk of cardiovascular diseases (CVDs). Therefore, we hypothesized that certain PCSK9 genetic variants may modify the association between LC n-3 PUFA intake and CVD risk.Objective: We determined whether a PCSK9 variant (rs11206510), which has been identified for early onset myocardial infarction (MI), modified the association of LC n-3 PUFAs with nonfatal MI risk in Costa Rican Hispanics.Design: We analyzed cross-sectional data from 1932 case subjects with a first nonfatal MI and 2055 population-based control subjects who were living in Costa Rica to examine potential gene-environment interactions. Two-sided P values <0.05 were considered significant. Results: We observed a significant interaction between the PCSK9 rs11206510 genotype and LC n-3 PUFA intake on nonfatal MI risk (P-interaction = 0.012). The OR of nonfatal MI was 0.84 (95% CI: 0.72, 0.98) per 0.1% increase in total energy intake from LC n-3 PUFAs in protective-allele (C-allele) carriers, whereas the corresponding OR (95% CI) in non-C-allele carriers was 1.02 (95% CI: 0.95, 1.10). Similar results were observed when we examined the association between docosahexaenoic acid, which is one type of LC n-3 PUFA, and nonfatal MI risk (P-interaction = 0.003). Conclusion: LC n-3 PUFA intake is associated with a lower risk of nonfatal MI in C-allele carriers of PCSK9 rs11206510 (n = 799) but not in non-C-allele carriers (n = 3188).
Background: Previous studies have indicated that the cardioprotective effects of long-chain (LC) n-3 (ω-3) polyunsaturated fatty acids (PUFAs) may vary across various ethnic populations. Emerging evidence has suggested that the gene-environment interaction may partly explain such variations. Proprotein convertase subtilisin/kexin type 9 (PCSK9) was shown to have a mutually regulating relation with LC n-3 PUFAs and also to reduce the risk of cardiovascular diseases (CVDs). Therefore, we hypothesized that certain PCSK9 genetic variants may modify the association between LC n-3 PUFA intake and CVD risk.Objective: We determined whether a PCSK9 variant (rs11206510), which has been identified for early onset myocardial infarction (MI), modified the association of LC n-3 PUFAs with nonfatal MI risk in Costa Rican Hispanics.Design: We analyzed cross-sectional data from 1932 case subjects with a first nonfatal MI and 2055 population-based control subjects who were living in Costa Rica to examine potential gene-environment interactions. Two-sided P values <0.05 were considered significant. Results: We observed a significant interaction between the PCSK9rs11206510 genotype and LC n-3 PUFA intake on nonfatal MI risk (P-interaction = 0.012). The OR of nonfatal MI was 0.84 (95% CI: 0.72, 0.98) per 0.1% increase in total energy intake from LC n-3 PUFAs in protective-allele (C-allele) carriers, whereas the corresponding OR (95% CI) in non-C-allele carriers was 1.02 (95% CI: 0.95, 1.10). Similar results were observed when we examined the association between docosahexaenoic acid, which is one type of LC n-3 PUFA, and nonfatal MI risk (P-interaction = 0.003). Conclusion: LC n-3 PUFA intake is associated with a lower risk of nonfatal MI in C-allele carriers of PCSK9rs11206510 (n = 799) but not in non-C-allele carriers (n = 3188).
Authors: Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; David Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Graham Nichol; Nina P Paynter; Pamela J Schreiner; Paul D Sorlie; Joel Stein; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2013-01-01 Impact factor: 29.690
Authors: Lu Qi; Layla Parast; Tianxi Cai; Christine Powers; Ernest V Gervino; Thomas H Hauser; Frank B Hu; Alessandro Doria Journal: J Am Coll Cardiol Date: 2011-12-13 Impact factor: 24.094
Authors: Frank B Hu; Leslie Bronner; Walter C Willett; Meir J Stampfer; Kathryn M Rexrode; Christine M Albert; David Hunter; JoAnn E Manson Journal: JAMA Date: 2002-04-10 Impact factor: 56.272
Authors: Qi Sun; Jing Ma; Hannia Campos; Kathryn M Rexrode; Christine M Albert; Dariush Mozaffarian; Frank B Hu Journal: Am J Clin Nutr Date: 2008-07 Impact factor: 7.045
Authors: Marcia C de Oliveira Otto; Jason H Y Wu; Ana Baylin; Dhananjay Vaidya; Stephen S Rich; Michael Y Tsai; David R Jacobs; Dariush Mozaffarian Journal: J Am Heart Assoc Date: 2013-12-18 Impact factor: 5.501